850+
Attendees
150+
Speakers
20+
Hours of Dedicated Networking
45%
In-House Ratio

Patent Litigation Europe 2027 - Advancing the Conversation on Insight, Debate and Case Law.

We’re delighted to welcome you back to the Beurs van Berlage, Amsterdam in 2027 for the sixth edition of Patent Litigation Europe.  

Building on the momentum of our 2026 rebrand, which expanded the event to encompass the full breadth of European patent litigation, this year's summit delivers an even richer programme across Europe's most litigious and dynamic sectors, combining brand-new content formats with deeper industry-focused discussions. 

PLE 2027 opens on Monday, 18th January with the cross-sector UPC Litigation Forum, providing an essential deep dive into the latest cases, rulings and strategies emerging from Europe’s transformative new court. 

 On Tuesday, 19th and Wednesday, 20th January, the agenda divides into two parallel tracks – Pharma & Biotech Patent Litigation Europe and Tech & Innovation Patent Litigation Europe – each delivering expert-led, sector-specific discussions tailored to your legal, commercial and strategic challenges.

UPC

Your opportunity to stay ahead of the legal, procedural and case law developments shaping Europe’s newest and most influential patent court. As the UPC continues to expand its reach and establish precedent, the UPC Litigation Forum offers a unique platform to connect with peers, benchmark litigation strategies, and gain practical insight into cross-border enforcement, jurisdictional trends, and evolving judicial thinking.

This event will bring together:
  • In-House IP Counsel & Legal Directors
  • Patent Litigators & Leading Law Firms
  • UPC Judges & Judicial Representatives
  • Patent Attorneys & Litigation Strategists
  • European Patent Offices & Institutions
  • Licensing & Enforcement Specialists
  • Cross-Border Dispute Experts
  • Regulatory & Competition Law Professionals


 

[harma

The ultimate meeting point for those at the forefront of protecting innovation and shaping patent litigation strategy in the global healthcare space. From navigating cross-border proceedings and shifting Bolar exemptions frameworks to mastering secondary patent, biosimilar, innovator-innovator and SPC litigation, this event empowers attendees with the tools, knowledge and connections to stay ahead in an evolving legal landscape.  

This event will bring together:
  • Innovator, Generic, Biotech & Biosimilar Companies 

  • Science-Driven Organisations  

  • In-House IP Litigators & Patent Prosecution Specialists  

  • External Patent Litigation Counsel & IP Law Firms 

  • Regulatory & Competition Law Experts  

  • Judges, Policy Makers & Institutional Authorities  


 

tech

Designed to keep you ahead of legal and regulatory developments shaping Europe's most dynamic industries, from AI and telecoms to software, semiconductors and beyond. Building on the success of its first edition in January 2026, this event offers a unique platform to connect with peers, benchmark approaches and gain the actionable knowledge needed to navigate complex, cross-border disputes with confidence. 

This event will bring together:
  • Technology Companies
  • Telecoms & Electronics Innovators
  • In-House IP Counsel & Legal Directors
  • Leading Patent Litigators & Law Firms
  • Patent Offices & Authorities
  • AI, SEP & FRAND Licensing Specialists
  • Competition Law Experts
     


 

Leading voices take to the stage


 

New for 2027

Dedicated cross-sector workshops, woven into the main programme

PLE 2027 introduces four interactive workshops shared by all delegates regardless of stream: the MedTech Disputes Workshop, the IP and Trade Secrets Workshop, the Soft IP Workshop and the Litigation Readiness Workshop. Running alongside the main plenary programme, these smaller, discussion-led sessions provide delegates with dedicated opportunities to explore practical challenges in greater depth, exchange experiences with peers and collaborate on practical, real-world solutions you can implement immediately.

The UPC Litigation Forum is now a full day with two concurrent tracks

Reflecting the UPC's global significance, the 2027 UPC Litigation Forum features two parallel tracks – UPC Strategy & Case Law and UPC & Global Litigation Strategy – alongside whole-audience keynote sessions, providing delegates with a full picture of the court’s latest strategy, case law and jurisdictional comparisons.

Expanded perspectives across the Tech & Innovation agenda

The Tech & Innovation Patent Litigation Europe 2027 programme delivers broader coverage across the full spectrum of technology patent litigation. New sessions explore AI, quantum computing, confidential information, NPE strategy, MedTech and evolving enforcement landscapes in China and the U.S., providing delegates with a rounded view of the challenges and opportunities shaping the sector.

A refreshed Pharma & Biotech programme, designed by and for the industry

Developed in close collaboration with senior in-house counsel, the Pharma & Biotech Patent Litigation Europe 2027 agenda introduces new sessions reflecting the full breadth of issues shaping modern life science patent litigation. From innovator-innovator litigation and the EU Pharma Package to treatment-related secondary patents, method of manufacturing claims, evidence gathering and damages, the programme equips delegates with actionable strategies for navigating today's evolving life science patent landscape.

2026 Attendees Include

Key themes and topics for this year

UPC case law & strategy
PIs, jurisdiction, forum choice

Preliminary injunctions after Insulet v EOFlow, forum selection across Munich, Dusseldorf, Mannheim and the Nordic-Baltic division, pre-litigation evidence strategy, and the Court of Appeal's 2026 rulings on inventive step, claim construction and costs.

SEP, FRAND & licensing
Royalty rates, injunctions, NPEs

Royalty rate determination, UK interim licences (Panasonic v Xiaomi, Nokia v Amazon), Panasonic v OPPO at the UPC, video codec licensing shifts, 6G portfolio positioning, and the growing role of NPEs and patent aggregators.

AI & emerging tech
AI patentability and litigation

AI's effect on patentability and inventorship, the EU AI Act and DSM Directive, AI-discovered therapeutics, quantum computing's implications for IP frameworks, and the use of AI tools across litigation workflows.

Life sciences disputes
Biosimilars, SPCs, secondary use

Biosimilar litigation (Humira, Stelara, Soliris, Keytruda), second medical use claims post-G1/23, innovator-vs-innovator disputes, Bolar exemption reform, SPC/PTE developments and sufficiency and plausibility standards after G2/21.

Cross-border strategy
Parallel proceedings and venue

Coordinating parallel UPC, national court and US proceedings, the long-arm jurisdiction debate following BSH v Electrolux, China and the UPC running in parallel, and the ITC as a competing global enforcement venue.

Trade secrets & antitrust
Evidence, confidentiality rules

Evidence, inspections and confidentiality across the UPC, Germany, France, the UK and the US, the deepening overlap between patent enforcement and competition law, and patent versus trade secret strategy.

audience 

Our Partners

Register Now

Three days. Three tracks. One unmissable summit for Europe's patent litigation community. Explore the latest UPC developments, Pharma & Biotech disputes, and Tech & Innovation cases with the people driving them. 18–20 January 2027, Amsterdam.